Duration of Fosamax (Alendronate) Treatment in Elderly Patients
Elderly patients should remain on Fosamax for 5 years initially, after which fracture risk should be reassessed to determine whether to continue treatment or initiate a bisphosphonate holiday. 1, 2
Initial Treatment Duration
The standard treatment duration for oral alendronate is 5 years 1, 3. This recommendation is based on high-quality evidence from randomized controlled trials demonstrating fracture reduction efficacy during this timeframe, with most pivotal studies evaluating treatment for 3-5 years 1.
Risk-Based Decision Making After 5 Years
After completing 5 years of alendronate therapy, the decision to continue or pause treatment depends critically on the patient's ongoing fracture risk 2:
Consider a Bisphosphonate Holiday if:
- T-score is greater than -2.5 2
- Patient has remained fracture-free during treatment 2
- Patient is at low-to-moderate fracture risk 3
Continue Treatment Beyond 5 Years (up to 10 years total) if:
- Fracture risk remains high 2
- T-score remains ≤ -2.5 2
- Patient has experienced fractures during treatment 2
- Patient has very high fracture risk (consider continuing 6-10 years) 2
The Bisphosphonate Holiday Concept
A unique feature of alendronate is its prolonged skeletal retention, which provides continued fracture protection even after discontinuation 4, 5. The landmark FLEX trial demonstrated that women who discontinued alendronate after 5 years maintained bone density levels at or above pretreatment values and showed no significant increase in nonvertebral fracture risk compared to those who continued treatment, though there was a modest increase in clinical vertebral fractures 4.
Duration of drug holiday: Up to 5 years for low-risk patients 2, 5, 6. The FDA label notes that optimal duration has not been definitively determined, but recommends considering discontinuation after 3-5 years for patients at low fracture risk 7.
Monitoring During a Drug Holiday
Reassess fracture risk every 2-4 years during the holiday period 3, 6. Resume treatment if:
- BMD decreases beyond the least significant change of the DXA machine 2
- Bone turnover markers increase significantly 2
- New fractures occur 2
- Fracture risk increases based on clinical assessment 2
Critical Caveats for Elderly Patients
Renal function matters: Fosamax is not recommended for patients with creatinine clearance <35 mL/min 7. Given age-related decline in renal function, assess creatinine clearance before continuing treatment in elderly patients.
Very high-risk patients should not take a holiday: Patients with recent fractures, multiple fractures, or very low bone density should continue treatment beyond 5 years 2. For these patients, treatment can extend to 10 years 2, 5.
Life expectancy considerations: In elderly patients with limited life expectancy (2-3 years), discontinuing alendronate after 5+ years of treatment is reasonable, as residual fracture protection persists 8.
Practical Algorithm
- Years 0-5: Treat all patients meeting osteoporosis treatment criteria
- At 5 years: Reassess fracture risk
- Low risk (T-score >-2.5, no fractures): Consider drug holiday with monitoring every 2-4 years
- Moderate risk: Consider continuing 1-2 more years, then reassess
- High/very high risk (T-score ≤-2.5, prior fractures, multiple risk factors): Continue treatment up to 10 years total
- At 10 years: Even high-risk patients should consider a drug holiday or switch to alternative therapy
The most recent and highest-quality guidance comes from the 2020 AACE/ACE guidelines 2 and the 2023 ACP living guideline 9, which emphasize individualized risk assessment but provide clear thresholds for decision-making. The 2017 ACP guideline 1 established the foundational 5-year treatment recommendation with strong evidence.